PHN031, for the indication of anti-osteoporosis, is ready for filing IND application.
• PHN031 is a small molecule fraction extracted from a Chinese herb.
• Pharmacology and mechanism of action: Studies show that PHN031 enhances bone formation in several animal models.
• Toxicology: All work in gene toxicology, acute toxicology, and 28 days toxicology studies have been completed with no drug related toxicity reported.
• CMC (Chemistry, Manufacturing and Control): All CMC documents are ready for IND application with ongoing stability studies to be completed.
• The active ingredients of this botanic drug have been identified and could be used as lead compounds for further chemical synthesis. The biological activity of these active ingredients includes enhancing osteoblast maturation or promoting erythropoiesis in bone marrow cells.

PHN033 is to be developed as a drug for the indication of diabetic vascular complications such as diabetic retinopathy
• PHN033 is a small molecule fraction extracted from a Chinese herb.
• Pharmacology and mechanism of action: Studies show that PHN033 increases degradation and clearances of AGE (advanced glycation end products) associated with diabetic conditions. PHN033 has been shown to enhance tissue regeneration of damaged retina, liver and kidney in animal models of diabetes induced by STZ or AGE-MSA.

Patents of PHN031 have been filed in US (application number: 11/274,775), Japan (application number: 2003-434707), Taiwan (application number: 92136872) and Australia (application number: 2004202986) and all of the patents are pending.

The patents of PHN033 have been filed in the US.